A Positive Role of c-Myc in Regulating Androgen Receptor and its Splice Variants in Prostate Cancer

[1]  P. Kantoff,et al.  Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. , 2019, European urology.

[2]  Lavinia A. Carabet,et al.  Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. , 2018, European journal of medicinal chemistry.

[3]  P. Nelson,et al.  Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer , 2018, The Journal of clinical investigation.

[4]  Walter N. Moss,et al.  The Epstein Barr virus circRNAome , 2018, PLoS pathogens.

[5]  Zhihua Liu,et al.  Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 , 2018, Proceedings of the National Academy of Sciences.

[6]  M. Gleave,et al.  Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells , 2018, Proceedings of the National Academy of Sciences.

[7]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[8]  Krishna R. Kalari,et al.  A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Menggang Yu,et al.  Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy , 2017, JAMA oncology.

[10]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[11]  Stefan J. Barfeld,et al.  c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks , 2017, EBioMedicine.

[12]  J. Whitfield,et al.  Strategies to Inhibit Myc and Their Clinical Applicability , 2017, Front. Cell Dev. Biol..

[13]  J. George,et al.  A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. , 2017, Cancer research.

[14]  Y. Dong,et al.  Emerging data on androgen receptor splice variants in prostate cancer. , 2016, Endocrine-related cancer.

[15]  David S. K. Lu,et al.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[16]  Shihua Sun,et al.  Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer , 2016, European urology.

[17]  S. Freedland,et al.  Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. , 2016, European urology.

[18]  Y. Oda,et al.  Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7. , 2016, Journal of the National Cancer Institute.

[19]  S. Plymate,et al.  Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. , 2016, Cancer research.

[20]  A. Gao,et al.  Lin28 induces resistance to anti‐androgens via promotion of AR splice variant generation , 2016, The Prostate.

[21]  James L. Chen,et al.  Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer , 2016, Oncotarget.

[22]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[23]  Fangting Wu,et al.  Regulation of androgen receptor splice variant AR3 by PCGEM1 , 2016, Oncotarget.

[24]  Ben S. Wittner,et al.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance , 2015, Science.

[25]  S. Gambhir,et al.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. , 2015, Cancer research.

[26]  Johan Lindberg,et al.  The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7 , 2015, Scientific Reports.

[27]  C. Evans,et al.  NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer , 2015, Molecular Cancer Therapeutics.

[28]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[29]  C. Evans,et al.  MP46-03 NF-KAPPAB2/P52:C-MYC:HNRNPA1 REGULATORY PATHWAY CONTROLS EXPRESSION OF ANDROGEN RECEPTOR SPLICE VARIANTS AND ENZALUTAMIDE SENSITIVITY IN PROSTATE CANCER , 2015 .

[30]  M. Kattan,et al.  A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. , 2015, European urology.

[31]  John T. Wei,et al.  RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. , 2014, The Lancet. Oncology.

[32]  Xueqi Fu,et al.  20(S)-Protopanaxadiol Inhibition of Progression and Growth of Castration-Resistant Prostate Cancer , 2014, PloS one.

[33]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[34]  F. Feng,et al.  Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy , 2014, International journal of radiation oncology, biology, physics.

[35]  Shihua Sun,et al.  Mechanisms of the androgen receptor splicing in prostate cancer cells , 2014, Oncogene.

[36]  C. Evans,et al.  MP24-07 NF-KAPPAB2/P52 INDUCES RESISTANCE TO ENZALUTAMIDE IN PROSTATE CANCER: ROLE OF ANDROGEN RECEPTOR AND ITS VARIANTS , 2014 .

[37]  Zhiyong Guo,et al.  Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy , 2014, Oncotarget.

[38]  P. Nelson,et al.  Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer , 2014, Clinical Cancer Research.

[39]  Anirban P. Mitra,et al.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.

[40]  Michael D. Nyquist,et al.  TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer , 2013, Proceedings of the National Academy of Sciences.

[41]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[42]  C. Evans,et al.  NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants , 2013, Molecular Cancer Therapeutics.

[43]  Daniel Bottomly,et al.  Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation , 2013, PloS one.

[44]  Xueqi Fu,et al.  20(S)‐protopanaxadiol‐aglycone downregulation of the full‐length and splice variants of androgen receptor , 2013, International journal of cancer.

[45]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[46]  Stephen R. Piccolo,et al.  A single-sample microarray normalization method to facilitate personalized-medicine workflows. , 2012, Genomics.

[47]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[48]  P. Nelson,et al.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.

[49]  Yingming Li,et al.  Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal* , 2012, The Journal of Biological Chemistry.

[50]  H. Kung,et al.  MicroRNA let-7c Suppresses Androgen Receptor Expression and Activity via Regulation of Myc Expression in Prostate Cancer Cells* , 2011, The Journal of Biological Chemistry.

[51]  W. Isaacs,et al.  A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities , 2011, The Prostate.

[52]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[53]  P. Nelson,et al.  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.

[54]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[55]  P. Stattin,et al.  Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival , 2011, PloS one.

[56]  N. Socci,et al.  Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.

[57]  P. Nelson,et al.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.

[58]  C. Bieberich,et al.  MYC and Prostate Cancer. , 2010, Genes & cancer.

[59]  G. Dreyfuss,et al.  Rapid-Response Splicing Reporter Screens Identify Differential Regulators of Constitutive and Alternative Splicing , 2010, Molecular and Cellular Biology.

[60]  H. Scher,et al.  Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer , 2009, Clinical Cancer Research.

[61]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[62]  E. Prochownik,et al.  Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice , 2009, Cancer Chemotherapy and Pharmacology.

[63]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[64]  Y. Asmann,et al.  A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy , 2008, PloS one.

[65]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[66]  Clement Ip,et al.  Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers , 2005, Molecular Cancer Therapeutics.

[67]  K. Burnstein,et al.  Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy , 2005, Journal of cellular biochemistry.

[68]  C. Ip,et al.  Prostate Specific Antigen Expression Is Down-Regulated by Selenium through Disruption of Androgen Receptor Signaling , 2004, Cancer Research.

[69]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[70]  R. Vessella,et al.  LuCaP 35: A new model of prostate cancer progression to androgen independence , 2003, The Prostate.

[71]  William C Hahn,et al.  Lentivirus-delivered stable gene silencing by RNAi in primary cells. , 2003, RNA.

[72]  Biaoyang Lin,et al.  The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[73]  U. Weidle,et al.  The transcriptional program of a human B cell line in response to Myc. , 2001, Nucleic acids research.

[74]  K. Burnstein,et al.  Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. , 1999, Molecular endocrinology.

[75]  J. Nevins,et al.  Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals , 1997, Molecular and cellular biology.

[76]  A. Belldegrun,et al.  Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. , 1997, Cancer research.

[77]  C. Ling,et al.  Transfected c-myc and c-Ha-ras modulate radiation-induced apoptosis in rat embryo cells. , 1994, Radiation research.

[78]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[79]  M. Gleave,et al.  AR‐V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate , 2017, The Journal of urology.

[80]  B. Trock,et al.  Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. , 2016, European urology.

[81]  Majid I. Alsagabi,et al.  Molecular and Cellular Pathobiology Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression , 2011 .

[82]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[83]  John T. Wei,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.

[84]  L. Hawthorn,et al.  Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. , 2003, Cancer research.

[85]  Roy G. Smith,et al.  Amplification, rearrangement, and elevated expression of c‐myc in the human prostatic carcinoma cell line LNCaP , 1989, The Prostate.